Menarini Group Highlights Efficacy of Elacestrant in Breast Cancer
At the recent annual meeting of the American Society of Clinical Oncology (ASCO), the Menarini Group introduced compelling new data regarding elacestrant's role in treating estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer (mBC). The presentation included an analysis of preliminary efficacy from the elacestrant combination therapy with everolimus and ribociclib as part of the ELEVATE study.
Insightful Findings from the ELEVATE Study
This update highlighted elacestrant's potential as a pivotal endocrine therapy backbone when combined with various targeted agents for patients with ER+/HER2- mBC. The ELEVATE study's findings underscore a substantial enhancement in the understanding of the efficacy and safety of elacestrant as a standalone treatment or combined with other therapies for mBC and early breast cancer.
The Combination Regimens
The ELEVATE clinical trial encompasses an array of treatment combinations, evaluating elacestrant alongside CDK4/6 inhibitors, which include palbociclib, abemaciclib, and ribociclib, as well as PI3K/AKT/mTOR pathway inhibitors like everolimus, alpelisib, and capivasertib. The results demonstrated promising preliminary progression-free survival (PFS) for the elacestrant paired with ribociclib and everolimus, leading to the establishment of a recommended phase 2 dose (RP2D) for these combinations.
Supported by Clinical Evidence
Hope S. Rugo, MD, from City of Hope Comprehensive Cancer Center, expressed optimism regarding the findings from the ELEVATE study. She remarked on the consistent efficacy and safety outcomes observed when elacestrant is combined with therapies like everolimus and ribociclib.
Exploring New Horizons
Moreover, the Menarini Group is advancing its investigation of elacestrant across different patient populations, including participants in the ongoing ELEGANT study focused on early breast cancer patients at high risk of recurrence. According to Elcin Barker Ergun, CEO of the Menarini Group, this underscores elacestrant's potential in providing valuable treatment options in the landscape of ER+/HER2- metastatic breast cancer.
Focus on Safety and Efficacy
Additional data reported during the meeting contained safety updates for four cohorts of the ELEVATE study, indicating that the combination of elacestrant with selected therapies aligns with the known safety profiles of those agents. The presented findings emphasize the notable effect of elacestrant when integrated with other cancer treatment modalities.
Upcoming Presentations
The anticipated presentations at ASCO featured several abstracts from the Menarini Stemline segment, including results from trials assessing elacestrant combinations with ribociclib and everolimus, as well as various other innovative studies assessing its therapeutic benefits in different cancer contexts.
About Elacestrant and Menarini Group
Elacestrant signifies a groundbreaking advancement in endocrine therapies, approved to treat postmenopausal women and men with ER-positive, HER2-negative metastatic breast cancer, specifically in cases where the disease has progressed following at least one line of endocrine therapy. The Menarini Group, a prominent pharmaceutical and diagnostics company, continues to focus on addressing high unmet medical needs across diverse therapeutic areas.
Frequently Asked Questions
What is elacestrant used for?
Elacestrant is primarily indicated for the treatment of ER-positive, HER2-negative metastatic breast cancer in adult men and postmenopausal women, especially after disease progression on prior endocrine therapy.
What findings were presented regarding elacestrant?
The findings from the ELEVATE study indicated positive preliminary results for combining elacestrant with ribociclib and everolimus, highlighting improvements in progression-free survival.
Who conducted the ELEVATE study?
The ELEVATE study was conducted by the Menarini Group in collaboration with Stemline Therapeutics, focusing on innovative treatment combinations for breast cancer.
What are the safety profiles associated with elacestrant?
Preliminary results indicate that elacestrant combinations align with known safety profiles of the respective therapies, suggesting it can be integrated effectively into existing treatment protocols.
How is Menarini Group involved in the oncology space?
The Menarini Group is actively developing and commercializing transformative oncology treatments, striving to meet the needs of patients facing various types of cancer through innovation and research.
